Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 5/2008

01.05.2008 | Original Article

Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET

verfasst von: L. S. Freudenberg, G. Antoch, A. Frilling, W. Jentzen, S. J. Rosenbaum, H. Kühl, A. Bockisch, R. Görges

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study sought to compare iodine-124 positron emission tomography/computed tomography (124I-PET/CT) and 2-[18F]fluoro-2-deoxy-d-glucose- (FDG-) PET in the detection of recurrent differentiated thyroid carcinoma (DTC) lesions in patients with increasing serum thyroglobulin (Tg), Tg-antibodies, or both, but without pathological cervical ultrasonography. We assessed the lesion detection accuracy of 124I-PET alone, CT alone, 124I-PET/CT, FDG-PET, and all these modalities combined.

Material and methods

The study included 21 patients (9 follicular, 12 papillary DTC) who had been rendered disease-free by thyroidectomy and radioiodine treatment (RIT) and followed up for 21-275 months after the last RIT. In all patients, FDG-PET was performed first. Within 1 week, 124I-PET/CT was performed 24 h after oral administration of 43 ± 11 MBq 124I. Imaging results were correlated with further clinical follow-up with (n = 12) or without (n = 9) post-study histology as the reference standard.

Results

The sensitivities for DTC lesion detection were: 124I-PET, 49%; CT, 67%; 124I-PET/CT, 80%; FDG-PET, 70%; and all modalities combined, 91%. For local recurrences (distant metastases), the sensitivities were: 124I-PET, 60% (45%); CT, 20% (84%); and FDG-PET, 65% (71%). One-third of lesions demonstrated pathological tracer uptake with both 124I- and FDG-PET, while two-thirds were positive with only one of these modalities.

Conclusion

Used together, 124I-PET and CT allow localization of foci of highly specific 124I uptake as well as non-iodine-avid lesions. The combination of 124I-PET/CT and FDG-PET improves restaging in recurrent DTC by enabling detection on whole-body scans of local recurrence or metastases that are often not found if only one of the methods or other imaging modalities are applied.
Literatur
1.
Zurück zum Zitat Frilling A, Görges R, Tecklenborg K, Gassmann P, Bockhorn M, Clausen M, et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000;128:1067-74.CrossRefPubMed Frilling A, Görges R, Tecklenborg K, Gassmann P, Bockhorn M, Clausen M, et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000;128:1067-74.CrossRefPubMed
2.
Zurück zum Zitat Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82-7.CrossRefPubMed Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82-7.CrossRefPubMed
3.
Zurück zum Zitat Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.PubMed Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.PubMed
4.
Zurück zum Zitat Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 2006;50:78-87.PubMed Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 2006;50:78-87.PubMed
5.
Zurück zum Zitat Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Görges R, et al. Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 2004;14:2092-8.CrossRefPubMed Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Görges R, et al. Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 2004;14:2092-8.CrossRefPubMed
6.
Zurück zum Zitat Freudenberg LS, Bockisch A, Jentzen W. 124I Positron emission tomographic dosimetry and positron emission tomography/computed tomography imaging in differentiated thyroid cancer. In: Biersack HJ, Grünwald F, editors. Thyroid cancer 2nd edn. Berlin: Springer; 2005. Freudenberg LS, Bockisch A, Jentzen W. 124I Positron emission tomographic dosimetry and positron emission tomography/computed tomography imaging in differentiated thyroid cancer. In: Biersack HJ, Grünwald F, editors. Thyroid cancer 2nd edn. Berlin: Springer; 2005.
7.
Zurück zum Zitat Jentzen W, Freudenberg L, Eising EG, Heinze M, Brandau W, Bockisch A. Segmentation of PET volumes by iterative image thresholding. J Nucl Med 2007;48:108-14.PubMed Jentzen W, Freudenberg L, Eising EG, Heinze M, Brandau W, Bockisch A. Segmentation of PET volumes by iterative image thresholding. J Nucl Med 2007;48:108-14.PubMed
8.
Zurück zum Zitat Fleming ID, Cooper JS, Henson DE (eds) (1997) AJCC cancer staging manual. 5th edn. American Joint Committee on Cancer. Lippincott-Raven, Philadelphia. Fleming ID, Cooper JS, Henson DE (eds) (1997) AJCC cancer staging manual. 5th edn. American Joint Committee on Cancer. Lippincott-Raven, Philadelphia.
9.
Zurück zum Zitat Freudenberg LS, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, et al. 124I-PET dosimetry in advanced thyroid cancer: Therapeutic impact. Nuklearmedizin 2007;46:121-8.PubMed Freudenberg LS, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, et al. 124I-PET dosimetry in advanced thyroid cancer: Therapeutic impact. Nuklearmedizin 2007;46:121-8.PubMed
10.
Zurück zum Zitat Knust EJ, Dutschka K, Weinreich R. Preparation of 124I solutions after thermodistillation of irradiated 124TeO2 targets. Appl Radiat Isot 2000;52:181-84.CrossRefPubMed Knust EJ, Dutschka K, Weinreich R. Preparation of 124I solutions after thermodistillation of irradiated 124TeO2 targets. Appl Radiat Isot 2000;52:181-84.CrossRefPubMed
11.
Zurück zum Zitat Antoch G, Kuehl H, Kanja J, Lauenstein TC, Schneemann H, Hauth E, et al. Dual modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004;230:879-85.CrossRefPubMed Antoch G, Kuehl H, Kanja J, Lauenstein TC, Schneemann H, Hauth E, et al. Dual modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004;230:879-85.CrossRefPubMed
12.
Zurück zum Zitat Furhang EE, Larson SM, Buranapong P, Humm JL, Furhang EE. Thyroid cancer dosimetry using clearance fitting. J Nucl Med 1999;40:131-36.PubMed Furhang EE, Larson SM, Buranapong P, Humm JL, Furhang EE. Thyroid cancer dosimetry using clearance fitting. J Nucl Med 1999;40:131-36.PubMed
13.
Zurück zum Zitat Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 1997;7:183-87.CrossRefPubMed Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 1997;7:183-87.CrossRefPubMed
14.
Zurück zum Zitat Dietlein M, Dressler J, Farahati J, Grunwald F, Leisner B, Moser E, et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin. 2004;43:115-20.PubMed Dietlein M, Dressler J, Farahati J, Grunwald F, Leisner B, Moser E, et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin. 2004;43:115-20.PubMed
15.
Zurück zum Zitat Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H.Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2). Nuklearmedizin 2003;42:123-5.PubMed Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H.Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2). Nuklearmedizin 2003;42:123-5.PubMed
16.
Zurück zum Zitat International Commission on Radiological Protection: Radiation dose to Patients from Radiopharmaceuticals, Publication 80. Oxford: Pergamon; 1999. International Commission on Radiological Protection: Radiation dose to Patients from Radiopharmaceuticals, Publication 80. Oxford: Pergamon; 1999.
17.
Zurück zum Zitat Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003 Jan 1;97(1):90-6.CrossRefPubMed Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003 Jan 1;97(1):90-6.CrossRefPubMed
18.
Zurück zum Zitat Rosario PW, de Faria S, Bicalho L, Alves MF, Borges MA, Purisch S, et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 2005;24:1385-9.CrossRefPubMed Rosario PW, de Faria S, Bicalho L, Alves MF, Borges MA, Purisch S, et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 2005;24:1385-9.CrossRefPubMed
19.
Zurück zum Zitat Torlontano M, Crocetti U, Augello G, D’Aloiso L, Bonfitto N, Varraso A, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 2006;91:60-3.CrossRefPubMed Torlontano M, Crocetti U, Augello G, D’Aloiso L, Bonfitto N, Varraso A, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 2006;91:60-3.CrossRefPubMed
20.
Zurück zum Zitat Görges R, Eising EG, Fotescu D, Renzing-Kohler K, Frilling A, Schmid KW, et al. Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. Eur J Ultrasound 2003;16:191-206.CrossRefPubMed Görges R, Eising EG, Fotescu D, Renzing-Kohler K, Frilling A, Schmid KW, et al. Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. Eur J Ultrasound 2003;16:191-206.CrossRefPubMed
21.
Zurück zum Zitat van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, et al. Cervical lymph node metastasis: assessment of radiological criteria. Radiology 1990;177:379-84.CrossRefPubMed van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, et al. Cervical lymph node metastasis: assessment of radiological criteria. Radiology 1990;177:379-84.CrossRefPubMed
22.
Zurück zum Zitat Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin North Am 1996;25:93-113.CrossRefPubMed Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin North Am 1996;25:93-113.CrossRefPubMed
23.
Zurück zum Zitat Freudenberg LS, Antoch G, Gorges R, Knust J, Pink R, Jentzen W, et al. Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report. Eur Radiol 2003;13:L19-23.CrossRefPubMed Freudenberg LS, Antoch G, Gorges R, Knust J, Pink R, Jentzen W, et al. Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report. Eur Radiol 2003;13:L19-23.CrossRefPubMed
24.
Zurück zum Zitat Grünwald F, Menzel C, Bender H, Palmedo H, Willkomm P, Ruhlmann J, et al. Comparison of F-18 FDG-PET with iodine-131 and Tc-99m-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-35.CrossRefPubMed Grünwald F, Menzel C, Bender H, Palmedo H, Willkomm P, Ruhlmann J, et al. Comparison of F-18 FDG-PET with iodine-131 and Tc-99m-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-35.CrossRefPubMed
25.
Zurück zum Zitat Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, et al. [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291-302.CrossRefPubMed Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, et al. [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291-302.CrossRefPubMed
26.
Zurück zum Zitat Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, et al. Value of FDG PET in papillary thyroid carcinoma with negative I-131 whole-body scan. J Nucl Med 1999;40:986-92.PubMed Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, et al. Value of FDG PET in papillary thyroid carcinoma with negative I-131 whole-body scan. J Nucl Med 1999;40:986-92.PubMed
27.
Zurück zum Zitat Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schuenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.PubMed Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schuenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.PubMed
28.
Zurück zum Zitat Grünwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.CrossRefPubMed Grünwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.CrossRefPubMed
29.
Zurück zum Zitat Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-60.CrossRefPubMed Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-60.CrossRefPubMed
Metadaten
Titel
Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET
verfasst von
L. S. Freudenberg
G. Antoch
A. Frilling
W. Jentzen
S. J. Rosenbaum
H. Kühl
A. Bockisch
R. Görges
Publikationsdatum
01.05.2008
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-007-0634-8

Weitere Artikel der Ausgabe 5/2008

European Journal of Nuclear Medicine and Molecular Imaging 5/2008 Zur Ausgabe